Showing 2241-2250 of 5909 results for "".
- Sanofi’s Intravitreal Gene Therapy Earns FDA Fast Track Designation for Geographic Atrophyhttps://modernod.com/news/sanofis-intravitreal-gene-therapy-earns-fda-fast-track-designation-for-geographic-atrophy/2482888/The FDA has granted fast track designation to SAR446597, a one-time intravitreal gene therapy for the treatment of geographic atrophy (GA) due to age-related macular degeneration (AMD). The fast track designation process aims to facilitate the developm
- ViaLase Announces Strategic Leadership Transitionshttps://modernod.com/news/vialase-announces-strategic-leadership-transitions/2482876/ViaLase announced changes to its executive leadership team as the company prepares for commercial launch and regulatory approvals in both the United States and Europe. Tibor Juhasz, PhD, founder and former Chief Executive Officer, has transitioned to
- Alcon to Acquire LumiThera, Maker of Photobiomodulation Device for the Treatment of Dry AMDhttps://modernod.com/news/alcon-to-acquire-lumithera-maker-of-photobiomodulation-device-for-the-treatment-of-dry-amd/2482873/In a move to bolster is vitreoretinal surgery portfolio, Alcon announced its intention to acquire LumiThera and its photobiomodulation (PBM) device for the treatment of dry early and intermediate dry AMD.
- Eyenovia Announces Rebranding and Corporate Name Change to Hyperion DeFi Inc.https://modernod.com/news/eyenovia-announces-rebranding-and-corporate-name-change-to-hyperion-defi-inc/2482871/Eyenovia announced a rebrand to Hyperion DeFi Inc., signaling a pivot toward decentralized finance. The rebranding reflects Hyperion DeFi’s cryptocurrency treasury reserve strategy, centered around HYPE, the native token of the Hyperliquid block
- Hadley and Notal Vision Partner to Empower Patients With Vision Loss Through Education and Leading Technologyhttps://modernod.com/news/hadley-and-notal-vision-partner-to-empower-patients-with-vision-loss-through-education-and-leading-technology/2482860/Hadley and Notal Vision announced a strategic partnership to bridge the gap between early detection, treatment monitoring, and adaptive living for patients with age-related macular degeneration (AMD). The collaboration will connect users of Notal Vision’s ForeseeHome and SCANLY Ho
- J&J Launches Daily Disposable Multifocal Toric Contact Lens: Acuvue Oasys Max 1-Day Multifocal for Astigmatismhttps://modernod.com/news/johnson-johnson-launches-daily-disposable-multifocal-toric-contact-lens-acuvue-oasys-max-1-day-multifocal-for-astigmatism/2482858/Johnson & Johnson announced the launch of Acuvue Oasys Max 1-Day Multifocal for Astigmatism, a daily disposable contact lens for people with both astigmatism and presbyopia. The company says this contact lens provides patients crisp, clear, stable vision at all distances and in all
- France First in EU to Reimburse Hoya MiYOSMART Lens for Childhood Myopiahttps://modernod.com/news/france-first-in-eu-to-reimburse-hoya-miyosmart-lens-for-childhood-myopia/2482856/France will begin reimbursing Hoya Vision Care’s MiYOSMART myopia control spectacle lenses for eligible children starting July 1. This move makes France as the first country in the European Union to provide public coverage for the lenses.
- TFOS DEWS III Report Published with Updated Guidelines for Diagnosis and Management of DEDhttps://modernod.com/news/tfos-dews-iii-report-published-for-updated-guidelines-for-diagnosis-and-management-of-ded/2482849/The Tear Film and Ocular Surface Society (TFOS) has released the TFOS DEWS III report, its third set of reports exploring the diagnosis and management of dry eye disease. The findings of the TFOS DEWS III report were published in the
- Navigate Patient Solutions Adds Ophthalmology Leaders to its Medical Advisory Boardhttps://modernod.com/news/navigate-patient-solutions-adds-ophthalmology-leaders-to-its-medical-advisory-board/2482835/Navigate Patient Solutions announced the addition of Vance Thompson, MD; David Cox, and Matthew P. Jensen to its Medical Advisory Board. Navigate is developing a patient engagement solution for ophthalmology. The startup partners with ophthal
- Rare Pediatric Disease Designation Granted for Ocugen's Gene Therapy for the Treatment of Stargardt Diseasehttps://modernod.com/news/rare-pediatric-disease-designation-granted-for-ocugens-gene-therapy-for-the-treatment-of-stargardt-disease/2482831/Ocugen announced that the FDA has granted Rare Pediatric Disease Designation for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations